Business context and reporting period
Tonix Pharmaceuticals Holding Corp. filed this Form 10-K for the fiscal year ended December 31, 2013; it is an annual report, not a standalone fourth-quarter report. The company is a development-stage pharmaceutical business focused on central nervous system disorders. Its lead candidate, TNX-102 SL, was in a Phase 2b/3 fibromyalgia trial; additional programs targeted PTSD and episodic tension-type headache. No product was approved or generating product revenue.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial statements generally present dollars in thousands.
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue and cost of goods sold | $0 | $0 |
| Research and development expense | $4.650 million | $2.583 million |
| General and administrative expense | $6.239 million | $4.078 million |
| Operating loss | $10.888 million | $6.662 million |
| Net loss | $10.884 million | $9.450 million |
| Net loss per share, basic and diluted | $3.37 | $5.58 |
| Cash used in operating activities | $8.517 million | $5.713 million |
| Cash at year-end | $8.202 million | $1.785 million |
Working capital was approximately $6.94 million at year-end. Current liabilities included $765,000 accounts payable, $1.166 million accrued expenses and $280,000 related-party promissory notes; the notes bear no interest and are payable on demand after one year from issuance. The filing reports no gross margin or other operating margin measure because the company had no revenue. No dividend was paid or expected in the foreseeable future.
Material changes versus 2012
- R&D expense rose 80%, mainly from TNX-102 SL development, manufacturing and clinical work. G&A expense rose 53%, including higher payroll, stock compensation, legal and investor-relations costs.
- Operating cash use increased by approximately $2.80 million. Net loss increased by approximately $1.43 million, despite 2012 having substantial financing-related interest expense and a warrant-liability fair-value charge that did not recur in 2013.
- Year-end cash increased following financing: the August 2013 offering generated approximately $10.04 million net, and warrant exercises generated approximately $4.63 million during 2013.
Outlook, risks and unusual items
- Management expected cash to fund operations for at least 12 months and forecast significantly higher R&D spending as trials advanced. After year-end, the January 2014 stock offering raised approximately $40.7 million net; the company also received approximately $4.8 million from warrant exercises through March 27, 2014.
- Management expected initial BESTFIT fibromyalgia trial results in Q4 2014, a PTSD proof-of-concept trial to begin in Q3 2014, and an initial TNX-201 clinical study in Q4 2014. These are plans, not assurances of completion or success.
- Key risks include clinical failure or delay, FDA requirements or rejection of the planned 505(b)(2) pathway, dependence on CROs and contract manufacturers, need for future financing and possible dilution, competition, reimbursement and market acceptance, and patent uncertainty. The company had never conducted a pivotal trial or submitted an NDA.
- The company had outstanding CRO commitments of approximately $4.5 million at year-end. It also entered into a non-U.S. license and cost-sharing arrangement for TNX-102 SL and TNX-201 through its Barbados subsidiary, with royalties on future net sales.
- Related-party matters include $280,000 in interest-free notes issued to affiliates of CEO Seth Lederman and, after year-end, purchases of biodefense intellectual property from entities controlled by him for $125,000 cash and 25,000 shares per agreement.
- The independent auditor issued an unqualified opinion on the financial statements. The filing states disclosure controls were effective, but its internal-control discussion refers to management’s conclusion as of December 31, 2012; investors should verify the intended period.
Important facts for investors to verify
- Whether BESTFIT results, the confirmatory fibromyalgia trial and planned PTSD and TNX-201 studies met the disclosed timelines and objectives.
- Current cash, operating cash burn, committed trial spending and the runway after the 2014 financing.
- The terms and potential dilution from outstanding warrants, options and subsequent equity issuances.
- Whether FDA feedback supports the planned 505(b)(2) applications and what additional clinical, safety or manufacturing requirements apply.
- Related-party transaction terms, including the biodefense asset purchases and the Barbados licensing and royalty arrangements.